# A Phase IV Study to Assess the Safety of EupentaTM Inj

> **NCT04056728** · PHASE4 · UNKNOWN · sponsor: **LG Chem** · enrollment: 3000 (estimated)

## Conditions studied

- Hepatitis B
- Diphtheria
- Haemophilus Influenzae Type B Infection
- Tetanus
- Pertussis

## Interventions

- **BIOLOGICAL:** Eupenta Inj.

## Key facts

- **NCT ID:** NCT04056728
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-23
- **Primary completion:** 2020-10-12
- **Final completion:** 2020-12-31
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2019-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04056728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04056728, "A Phase IV Study to Assess the Safety of EupentaTM Inj". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04056728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*